论文部分内容阅读
目的探讨18F-FDG PET/CT显像联合血清CA153、CEA在乳腺癌术后随访过程中的应用价值。方法选取沈阳军区总医院2012—2016年收治68例乳腺癌术后患者作为研究对象。所有患者均行18F-FDG PET/CT显像和常规乳腺影像检查(CT、超声和MRI),结合临床病理及随访结果,将PET/CT显像结果与常规影像检查进行比较,探讨肿瘤标志物CA153和CEA与PET/CT显像结果的相关性。结果与常规乳腺检查(CT、超声和MRI)比较,PET/CT具有更高的灵敏度和特异性,可以发现更多转移灶。CA153、CEA单独诊断的特异度分别为93.3%、96.6%,灵敏度为55.3%、42.1%,两者联合诊断的灵敏度为68.4%,较单独检测差异无统计学意义(P>0.05)。PET/CT真阳性的患者中,血清CA153的水平明显高于真阴性组(P<0.05),血清CEA水平比较,差异无统计学意义(P>0.05)。结论与常规检查方法(CT、超声和MRI)比较,PET/CT显像在乳腺癌术后随访过程中监测复发和转移具有优势,PET/CT真阳性患者的血清CA153水平较真阴性患者显著升高,表明肿瘤标志物在随访过程中具有重要的监测价值。
Objective To investigate the value of 18F-FDG PET / CT imaging combined with serum CA153 and CEA in the follow-up of postoperative breast cancer. Methods Shenyang Military Region General Hospital from 2012 to 2016, 68 cases of breast cancer patients treated as the research object. All patients underwent 18F-FDG PET / CT imaging and routine breast imaging (CT, ultrasound and MRI), combined with clinical and pathological findings and follow-up results, PET / CT imaging results compared with conventional imaging to explore the tumor markers Correlation of CA153 and CEA with PET / CT imaging findings. Results Compared with conventional breast examination (CT, ultrasound and MRI), PET / CT had higher sensitivity and specificity and more metastases were found. The specificity of single diagnosis of CA153 and CEA were 93.3% and 96.6% respectively, the sensitivity was 55.3% and 42.1%, respectively. The sensitivity of combined diagnosis of CA153 and CEA was 68.4%. There was no significant difference between the two methods (P> 0.05). Serum CA153 levels in patients with true PET / CT were significantly higher than those in the true negative group (P <0.05). There was no significant difference in serum CEA levels between the two groups (P> 0.05). Conclusion Compared with routine examination (CT, ultrasound and MRI), PET / CT imaging has the advantage of monitoring recurrence and metastasis in postoperative follow-up of breast cancer patients. The level of serum CA153 in PET / CT positive patients is significantly higher than that in true negative patients , Indicating that tumor markers in the follow-up process has an important monitoring value.